Loading...
•
Dec 31, 2022
Jaguar Health Q4 2022 Earnings Report
Jaguar Health's prescription revenues increased significantly, driven by Mytesi growth and Canalevia-CA1 commercial availability.
Key Takeaways
Jaguar Health reported a 57% increase in prescription product net revenue for Q4 2022 compared to Q4 2021, reaching $3.3 million. The growth was attributed to the continued success of Mytesi and the introduction of Canalevia-CA1. The company is focused on expanding clinical trials and exploring new indications for crofelemer.
Prescription product net revenue increased by 57% in Q4 2022 compared to Q4 2021.
Mytesi revenue continued to grow for the sixth consecutive quarter.
Patient enrollment in the OnTarget Phase 3 clinical trial is at approximately 80% and expected to complete in Q2 2023.
The company plans to support investigator-initiated proof-of-concept studies of crofelemer for short bowel syndrome and congenital diarrheal disorders.
Forward Guidance
Jaguar Health is focused on completing enrollment in the OnTarget trial, supporting investigator-initiated studies, and submitting an IND application for crofelemer.
Positive Outlook
- Patient enrollment in OnTarget trial expected to complete in Q2 2023.
- Planning to support investigator-initiated proof-of-concept studies of crofelemer in 2023.
- Potential early patient access to crofelemer in Europe in 2024.
- Plans to submit an IND application in Q2 2023 to FDA for crofelemer for microvillus inclusion disease.
- Transition to limited distribution network of specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...